Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis

被引:2
|
作者
Garrido, Manuel M. [1 ]
Ribeiro, Ruy M. [2 ]
Krueger, Kimberly [3 ,4 ]
Pinheiro, Luis C. [5 ,6 ]
Guimaraes, Joao T. [7 ,8 ,9 ]
Holdenrieder, Stefan [4 ]
机构
[1] Ctr Hosp Univ Lisboa, Dept Clin Pathol, Lisbon, Portugal
[2] Univ Lisbon, Dept Lab Med, Fac Med, Lisbon, Portugal
[3] Univ Lisbon, Biomath Lab, Fac Med, Lisbon, Portugal
[4] Tech Univ Munich, Munich Biomarker Res Ctr, Inst Lab Med, Deutsch Herzzentrum Munchen, Munich, Germany
[5] Ctr Hosp Univ Lisboa Cent, Dept Urol, Lisbon, Portugal
[6] Univ Nova Lisboa, Dept Urol, Fac Ciencias Med, Lisbon, Portugal
[7] Ctr Hosp Univ Sao Joao, Dept Clin Pathol, Porto, Portugal
[8] Univ Porto, Dept Biomed, Fac Med, Porto, Portugal
[9] Univ Porto, Inst Saude Publ, EPIUnit, Porto, Portugal
来源
IN VIVO | 2021年 / 35卷 / 04期
关键词
Prostate cancer; circulating nucleosomes; cell death detection ELISA; immunogenic cell death markers; sRAGE; HMGB1; CELL-DEATH; ACTIVE SURVEILLANCE; RAGE; PROGRESSION; BIOMARKERS; APOPTOSIS; THERAPY; EVASION; SERUM;
D O I
10.21873/invivo.12492
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. Patients and Methods: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. Results: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). Conclusion: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.
引用
收藏
页码:2207 / 2212
页数:6
相关论文
共 50 条
  • [1] Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
    Wittwer, Christin
    Boeck, Stefan
    Heinemann, Volker
    Haas, Michael
    Stieber, Petra
    Nagel, Dorothea
    Holdenrieder, Stefan
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (11) : 2619 - 2630
  • [2] HMGB1, nucleosomes and sRAGE as new prognostic serum markers after multiple trauma
    Stahl, Juliane Barbara
    Hoecherl, Eduard F.
    Durner, Juergen
    Nagel, Dorothea
    Wolf, Konrad
    Holdenrieder, Stefan
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2016, 40 (03): : 165 - 173
  • [3] Clinical relevance of circulating nucleosomes in cancer
    Holdenrieder, Stefan
    Nagel, Dorothea
    Schalhorn, Andreas
    Heinemann, Volker
    Wilkowski, Ralf
    von Pawel, Joachim
    Raith, Hannelore
    Feldmann, Knut
    Kremer, Andreas E.
    Mueller, Susanne
    Geiger, Sandra
    Hamann, Gerhard F.
    Seidel, Dietrich
    Stieber, Petra
    CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, 2008, 1137 : 180 - 189
  • [4] Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies
    Schroeder, Lars
    Rupp, Alexander B. A.
    Gihr, Kathrin M. E.
    Kobilay, Makbule
    Domroese, Christian M.
    Mallmann, Michael R.
    Holdenrieder, Stefan
    CANCERS, 2023, 15 (20)
  • [5] Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer
    Zhao, Chu-Biao
    Bao, Ji-Ming
    Lu, Yong-Jie
    Zhao, Tong
    Zhou, Xin-Hua
    Zheng, Da-Yong
    Zhao, Shan-Chao
    AMERICAN JOURNAL OF CANCER RESEARCH, 2014, 4 (04): : 369 - 377
  • [6] Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
    Stoetzer, Oliver J.
    Fersching, Debora M. I.
    Salat, Christoph
    Steinkohl, Oliver
    Gabka, Christian J.
    Hamann, Ulrich
    Braun, Michael
    Feller, Axel-Mario
    Heinemann, Volker
    Siegele, Barbara
    Nagel, Dorothea
    Holdenrieder, Stefan
    TUMOR BIOLOGY, 2013, 34 (01) : 81 - 90
  • [7] The association between plasma HMGB1 and sRAGE and clinical outcome in intracerebral hemorrhage
    Lei, Chunyan
    Geng, Jia
    Zhong, Lianmei
    JOURNAL OF NEUROIMMUNOLOGY, 2020, 345
  • [8] Changes of HMGB1 and sRAGE during the recovery of COPD exacerbation
    Zhang, Yonghong
    Li, Shaojun
    Wang, Guizuo
    Han, Dong
    Xie, Xinming
    Wu, Yuanyuan
    Xu, Jing
    Lu, Jiamei
    Li, Fengjuan
    Li, Manxiang
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 734 - 741
  • [9] Immunogenic cell death markers HMGB1 and sRAGE as new predictive and prognostic serum biomarkers in cancer disease
    Wittwer, Christin
    Holdenrieder, Stefan
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2013, 37 (01): : 29 - 51
  • [10] Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications
    Barreiro-Alonso, Aida
    Camara-Quilez, Maria
    Salamini-Montemurri, Martin
    Lamas-Maceiras, Monica
    Vizoso-Vazquez, Angel
    Rodriguez-Belmonte, Esther
    Quindos-Varela, Maria
    Martinez-Iglesias, Olaia
    Figueroa, Angelica
    Cerdan, Maria-Esperanza
    CANCERS, 2019, 11 (11)